Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia.

Inami, M

Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. [electronic resource] - Leukemia May 2007 - 1103-4 p. digital

Publication Type: Case Reports; Letter

0887-6924

10.1038/sj.leu.2404591 doi


Adult
Antineoplastic Agents--therapeutic use
Benzamides
Humans
Imatinib Mesylate
Janus Kinase 2--genetics
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Male
Mutation
Piperazines--therapeutic use
Polycythemia--etiology
Pyrimidines--therapeutic use